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ABSTRACT The case of a 26-year-old male patient with perifolliculitis 
capitis abscedens et suffodiens (PCAS) who later developed hidradenitis 
suppurativa (HS) and exacerbation of acne is presented. The patient did 
not respond well to conventional treatment including isotretinoin and 
oral antibiotics. Quality of life was significantly impaired. After introduc-
tion of anti-tumor necrosis factor-alpha (TNF-α) treatment, the patient’s 
clinical picture improved dramatically and quality of life increased. The 
treatment has been well tolerated by the patient for 15 months at time 
of writing this report.
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INTRODUCTION
Perifolliculitis capitis abscedens et suffodiens 
(PCAS), also known as dissecting cellulitis of the scalp, 
is a rare, chronic and relapsing inflammatory disease 
of unknown etiology. It was first described by Spritzer 
in 1903 and later named by Hoffmann in 1908 (1,2).
The condition is characterized by painful, fluctu-
ant pustules, nodules, abscesses, and sinuses that 
result in patchy areas of atrophic, hypertrophic, and 
keloidal scars, as well as alopecia. Lesions are primar-
ily located on the occipital scalp or vertex; however, 
other sections of the scalp can be affected (3). The 
disease generally exhibits a chronic course with fre-
quent flare-ups.
Treatment is usually difficult and often unsuccess-
ful, with relapses occurring regularly after discontinu-
ation of treatment. Conventional therapies reported 
in the literature for the treatment of PCAS include low 
dose oral zinc, isotretinoin, minocycline, sulfa drugs, 
tetracyclines, prednisone, intralesional triamcino-
lone, incision and drainage, dapsone, antiandrogens 
(in women), topical clindamycin, topical isotretinoin, 
X-ray epilation and ablation, ablative C02 lasers, hair 
removal lasers (800 nm and 694 nm), and surgical 
excision. Newer treatments reported include tumor 
necrosis factor inhibitors, quinolones, macrolide an-
tibiotics, rifampin, alitretinoin, metronidazole, and 
high-dose zinc sulphate (4). Generally, acute flares are 
best treated with broad-spectrum antibiotics. Good 
results have been reported in patients subsequently 
treated with isotretinoin, but the number of reports 
is small, dosing schedules are variable, and long term 
follow-up is negligible (3). 
PCAS may occur along with hidradenitis suppura-
tiva and acne conglobata, constituting the follicular 
occlusion triad. Although these diseases occur in dif-
ferent areas of the body, they show the same histo-
logic changes and share a common mechanism of 
pathogenesis: follicular hyperkeratosis and plugging 
ACTA DERMATOVENEROLOGICA CROATICA
256 ACTA DERMATOVENEROLOGICA CROATICA
leading to follicular occlusion, dilatation, rupture, and 
secondary bacterial infection. Infections are most fre-
quently caused by Staphylococcus aureus and Staphy-
lococcus epidermidis. Keratin and bacteria from rup-
tured follicles can initiate a neutrophilic and granulo-
matous response (5). 
Hidradenitis suppurativa may also occur in other 
rare syndromes (e.g. Bazex-Dupré-Christol syndrome, 
Dowling-Degos disease, keratitis, ichthyosis, and 
deafness (KID) syndrome) which require different 
management; however, our patient revealed no typi-
cal symptoms or signs that can be associated with 
another syndrome (6).
Conditions to consider in the differential diagnosis 
of PCAS include pseudopelade of Brocq, inflammato-
ry tinea capitis, folliculotropic mycosis fungoides, and 
central centrifugal scarring alopecia (7).  
CASE REPORT
A 26-year-old male patient presented with patchy 
hair loss overlying inflammatory papules, pustules, 
yellow crusts, and tender, fluctuant, suppurative 
nodules on the frontal scalp. Several nodules formed 
confluent conglomerates, which discharged purulent 
secretion when pressed not only in close proximity 
but also from more distant areas. This presentation 
indicated the presence of fistulae and interconnect-
ing sinuses. The findings progressively worsened over 
the course of 2 months with an increase in the num-
ber of nodules and affected areas of the scalp, along 
with swelling of regional lymph nodes.  
Skin biopsy taken from the scalp revealed an epi-
dermis with 3 hair follicles showing dilated infundib-
ulums containing keratin, and an infiltrate of mono-
nuclear cells surrounding vessels within the dermis. 
No abscess was found. Potassium hydroxide smears 
did not show any fungal elements, and culture of the 
material was also sterile. Bacterial analysis of the scalp 
swab revealed only saprophytic bacteria. The patient’s 
overall physical examination was normal. Routine 
laboratory tests showed increased erythrocyte sedi-
mentation rate (ESR), leukocytosis, dyslipidemia, and 
Figure 4. Axilla – 8 months following initiation of anti-tu-
mor necrosis factor-alpha.
Figure 1. Scalp lesions before initiating therapy with anti-
tumor necrosis factor-alpha.
Figure 2. Axillary lesions before initiating therapy with anti-
tumor necrosis factor-alpha.
Figure 3. Scalp – 6 months following initiation of anti-tu-
mor necrosis factor-alpha.
Sjerobabski Masnec and Franceschi Acta Dermatovenerol Croat
Perifoliculitis capitis abscedens et suffodiens  2018;26(3):255-259




Badaoui et al. (13) 1 patient NA infliximab no improvement




infliximab 5 mg/kg at 
8-week intervals for 12 
months
hair beginning to regrow after 
second treatment; 1 year after 
discontinuing treatment no signs of 
relapse
Mansouri et al. (11)
1. 48/male
2. 27/male
1. multiple antibiotics, 
zinc sulfate, dapsone, 
isotretinoin, systemic 
CS, surgical excision 
and drainage





80 mg on day 0, 
40 mg on day 7, 40 
mg every other week 
thereafter
2. infliximab 
5 mg/kg at weeks 0, 2, 
6 followed by 8 week 
intervals (20 months and 
continuing)
1. after 1 month –improvement; at 5 
months DLQI from 21 to 10
2. reduction of symptoms, 
inflammation and odor within 3 
months, continuous improvement; 











80 mg on day 0, 40 mg 
on day 7, 40 mg every 
other week thereafter (2 
years and continuing)
after 1 month significant 
improvement; after 7 months 
complete clearance of inflammatory 
lesions













1., 2., 3. adalimumab 
80 mg on day 0, 40 mg 
on day 7, 40 mg every 
other week thereafter
1., 2., 3. clinical symptoms subsided 
within 8 weeks of treatment; after 
3 months clinical activity and  
subjective symptoms were reduced
3. after 4 months of successful treat-
ment, disease  returned within 4 
weeks









1. total clearance of disease within
3 months 








80 mg on day 0, 1, 14, 
40 mg on day 28, 40 mg 
every week thereafter
excellent response after only 10 
weeks, DLQI 27 to 1








40 mg ×2 week 1, 
40 mg week 2, 
40 mg every other week
pain and purulent discharge 
stopped within 1 month; at 5-month 










5 mg/kg at weeks 0, 2, 
and 6
reduction of inflammation, 
secretion,  pain and




CS: corticosteroid; NA: not available
Table 1. Cases of perifolliculitis capitis abscedens et suffodiens (PCAS) treated with anti-tumor necrosis 
factor-alpha (TNF-α) inhibitors
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increased serum gamma-glutamyltransferase levels. 
Patient body mass index was 35.8. Patient history re-
vealed he was a smoker.
Quality of life, measured using the Dermatology 
Life Quality Index (DLQI), was significantly reduced.
Initially, the patient was treated with a systemic 
retinoid, isotretinoin, at a dose of 0.64 mg/kg over 10 
months, achieving a cumulative dose of 150 mg/kg. 
After 3 months of treatment with isotretinoin, the 
lesions on the scalp slightly improved, no new nod-
ules were present, and secretion was milder in extent. 
However, the patient developed hidradenitis sup-
purativa, manifesting as painful furuncles in the left 
axilla and later in the right axilla, inguinum, and lower 
abdomen, at places forming interconnecting sinuses, 
and partially healing with atrophic or hypertrophic 
livid scars. These findings classified as Hurley stage 2 
hidradenitis suppurativa (8). 
The patient additionally developed exacerbation 
of facial acne during treatment. After 10 months of 
therapy, the inflammation and secretions on the scalp 
subsided, while lesions in the inguinum and axillary 
area worsened and facial acne also persisted. After 
failure of isotretinoin therapy, treatment with multi-
ple antibiotics was started over a course of 12 weeks; 
however, no significant improvement was achieved. 
Tumor necrosis factor alpha (TNF-α) inhibitors 
have been shown to be successful in treating hi-
dradenitis suppurativa; thus, treatment with adali-
mumab was considered (9). The patient was tested 
for tuberculosis, HIV, and hepatitis B and C, with all 
results coming back negative. The patient was then 
initiated on adalimumab 80 mg on days 0, 1, and 14 
followed by 40 mg on day 28 and every week there-
after (10). Response to treatment was excellent after 
only 10 weeks of therapy. A significant improvement 
of all symptoms was observed, with reduced secre-
tion, pain, and inflammatory changes on the scalp, 
absence of new nodules and sinus tracts in the bi-
lateral axilla, inguinum, and pubic region, as well as 
clearing of facial acne. The patient’s DLQI had also re-
duced significantly from 27 to 1. As if this writing, the 
treatment has been well tolerated by the patient for 
15 months, with the patient receiving adalimumab 
40 mg injections every week.
DISCUSSION
Treatment of perifolliculitis capitis abscedens et 
suffodiens and hidradenitis suppurativa is difficult, 
often disappointing, and unpredictable. PCAS often 
persists or recurs despite different treatment modali-
ties including topical and oral antibiotics, isotretinoin, 
topical, intralesional and systemic steroids, incision 
and drainage, zinc sulfate, and procedural therapies 
including laser-assisted epilation, carbon dioxide 
laser ablation, and wide surgical excision with skin 
grafting (4). 
Treatment with TNF-α inhibitors has been report-
ed in recent literature (Table 1) as a new approach in 
the treatment of PCAS (11). Adalimumab is a mono-
clonal antibody that binds to TNF-α, a pro-inflamma-
tory cytokine that is thought to play an important role 
in the pathogenesis of follicular occlusion disorders. 
In July 2015, the European Medicines Agency (EMA) 
approved the use of adalimumab for treatment of ac-
tive moderate to severe hidradenitis suppurativa in 
patients older than 12 years of age with inadequate 
response to conventional systemic hidradenitis ther-
apy (12). Since PCAS and HS are believed to exhibit 
the same pathogenesis and frequently occur in the 
same patient, TNF-α inhibitors may be an effective 
option in the management of PCAS, as was demon-
strated in our patient.
References:
1. Spritzer L. Dermatitis follicularis et perifollicularis 
conglobata. Dermatol Zeitschrift. 1903;10:109-
20.
2. Hoffmann E. Folliculitis et perifolliculitis capitis 
abscedens et suffodiens: case presentation. Der-
matol Zeitschrift. 1908;15:122-3.
3. Wolff H. Diseases of hair. In: Burgdorf W, Plewig 
G, Wolff HH, Landthaler M, ed. Braun Falco’s Der-
matology. 3rd completely revised edition. Berlin, 
Heidelberg, New York: Springer-Verlag; 2009. pp. 
1029-59. 
4. Scheinfeld N. Dissecting cellulitis (Perifolliculitis 
Capitis Abscedens et Suffodiens): a comprehen-
sive review focusing on new treatments and fin-
dings of the last decade with commentary com-
paring the therapies and causes of dissecting 
cellulitis to hidradenitis suppurativa. Dermatol 
Online J. 2014;20:22692.
5. Chicarilli ZN. Follicular occlusion triad: hidradenitis 
suppurativa, acne conglobata, and dissecting cel-
lulitis of the scalp. Ann Plast Surg. 1987;18:230-7.
6. Gasparic J, Theut Riis P, Jemec GB. Recognizing 
syndromic hidradenitis suppurativa: a review 
of the literature. J Eur Acad Dermatol Venereol. 
2017;31:1809-16.
7. Lugović Mihić L, Tomas D, Šitum M, Krolo I, Šebetić 
K, Sjerobabski Masnec I, et al. Perifolliculitis capitis 
abscedens et suffodiens in a caucasian: diagnostic 
and therapeutic challenge. Acta Dermatovenerol 
Croat. 2011;19:98-102.
Sjerobabski Masnec and Franceschi Acta Dermatovenerol Croat
Perifoliculitis capitis abscedens et suffodiens  2018;26(3):255-259
259ACTA DERMATOVENEROLOGICA CROATICA
8. Zouboulis CC, Del Marmol V, Mrowietz U, Prens 
EP, Tzellos T, Jemec GB. Hidradenitis suppurativa/
acne inversa: criteria for diagnosis, severity as-
sessment, classification and disease evaluation. 
Dermatology. 2015;231:184-90.
9. Kimball AB, Okun MM, Williams DA, Gottlieb AB, 
Papp KA, Zouboulis CC, et al. Two phase 3 trials 
of adalimumab for hidradenitis suppurativa. New 
Engl J Med. 2016;375:422-34.
10. Zouboulis CC, Desai N, Emtestam L, Hunger RE, 
Ioannides D, Juhász I, et al. European S1 guide-
line for the treatment of hidradenitis suppura-
tiva/acne inversa. J Eur Acad Dermatol Venereol. 
2015;29:619-44.
11. Mansouri Y, Martin-Clavijo A, Newsome P, Kaur 
MR. Dissecting cellulitis of the scalp treated with 
tumour necrosis factor-a inhibitors: experience 
with two agents. Br J Dermatol. 2016;174:916-8.
12. European Medicines Agency: EMA [Internet]. Lon-
don, United Kingdom; 1995-2017 [cited 2017 Jun 




13. Badaoui A, Reygagne P, Cavelier-Balloy B, Pin-
quier L, Deschamps L, Crickx B, et al. Dissecting 
cellulitis of the scalp: a retrospective study of 51 
patients and review of literature. Br J Dermatol. 
2016;174:421-3.
14. Brandt HR, Malheiros AP, Teixeira MG, Machado 
MC. Perifolliculitis capitis abscedens et suffodiens 
successfully controlled with infliximab. Br J Der-
matol. 2008;159:506-7.
15. Martin-García RF, Rullán JM. Refractory dissecting 
Cellulitis of the Scalp Successfully controlled with 
Adalimumab. P R Health Sci J. 2015;34:102-4.
16. Navarini AA, Trüeb RM. 3 cases of dissecting cellu-
litis of the scalp treated with adalimumab: control 
of inflammation within residual structural disease. 
Arch Dermatol. 2010;146:517-20.
17. Sand FL, Thomsen SF. Off-label use of TNF-alpha 
inhibitors in a dermatological university depart-
ment: retrospective evaluation of 118 patients. 
Dermatol Ther. 2015;28:158-65.
18. Sukhatme SV, Lenzy YM, Gottlieb AB. Refractory 
dissecting cellulitis of the scalp treated with adali-
mumab. J Drugs Dermatol. 2008;7:981-3.
19. Wollina U, Gemmeke A, Koch A. Dissecting Celluli-
tis of the Scalp Responding to Intravenous Tumor 
Necrosis Factor-alpha Antagonist. J Clin Aesthet 
Dermatol. 2012;5:36-9.
Sjerobabski Masnec and Franceschi Acta Dermatovenerol Croat
Perifoliculitis capitis abscedens et suffodiens  2018;26(3):255-259
